This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.63% and 0.63%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 4.88% and 1.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Top Research Reports for Microsoft, Salesforce & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Salesforce, Inc. (CRM) and United Parcel Service, Inc. (UPS).
Should You Buy Agios Pharmaceuticals (AGIO) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
by Zacks Equity Research
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.
Wall Street Analysts Believe Agios Pharmaceuticals (AGIO) Could Rally 39.16%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same.
Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 142.14% and 2.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Alaunos (TCRT) have performed compared to their sector so far this year.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.